2013
DOI: 10.1021/jm400204k
|View full text |Cite
|
Sign up to set email alerts
|

Discovery of Thieno[3,2-d]pyrimidine-6-carboxamides as Potent Inhibitors of SIRT1, SIRT2, and SIRT3

Abstract: The sirtuins SIRT1, SIRT2, and SIRT3 are NAD(+) dependent deacetylases that are considered potential targets for metabolic, inflammatory, oncologic, and neurodegenerative disorders. Encoded library technology (ELT) was used to affinity screen a 1.2 million heterocycle enriched library of DNA encoded small molecules, which identified pan-inhibitors of SIRT1/2/3 with nanomolar potency (e.g., 11c: IC50 = 3.6, 2.7, and 4.0 nM for SIRT1, SIRT2, and SIRT3, respectively). Subsequent SAR studies to improve physiochemi… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

10
164
0
1

Year Published

2013
2013
2019
2019

Publication Types

Select...
5
2

Relationship

0
7

Authors

Journals

citations
Cited by 179 publications
(177 citation statements)
references
References 47 publications
10
164
0
1
Order By: Relevance
“…S1A). Both EX-527 and C28 decreased the SIRT1-DBC1 luciferase signal in a dose-dependent manner, with an efficacy that parallels their IC 50 values for SIRT1 inhibition in vitro 36,37 ( Fig. 5C and D).…”
Section: Resultsmentioning
confidence: 62%
See 3 more Smart Citations
“…S1A). Both EX-527 and C28 decreased the SIRT1-DBC1 luciferase signal in a dose-dependent manner, with an efficacy that parallels their IC 50 values for SIRT1 inhibition in vitro 36,37 ( Fig. 5C and D).…”
Section: Resultsmentioning
confidence: 62%
“…37 Titrations of inhibitor spanning several orders in magnitude were performed on cells expressing either SIRT1/DBC1 luciferase-component fusions, or Bach1/Mafk-luciferase component fusions. Bach1 and Mafk have previously been reported to interact in numerous cells types 49 and served as a negative control in these experiments.…”
Section: Resultsmentioning
confidence: 99%
See 2 more Smart Citations
“…Figure 6 shows the 3D and 2D ligand receptor interactions demonstrated by molecular docking. Interestingly, the crucial interaction regions reported in the literature for known inhibitors (small molecules or peptides) were observed for 2-ME at both the canonical inhibitor and allosteric sites (42)(43)(44)(45)(46) Figure 6B-E.…”
Section: Molecular Dockingmentioning
confidence: 75%